Due to the reciprocal regulatory relationship between CD147 and Nrf2, which affects clinical outcome, targeting CD147 could suppress Nrf2 expression and further increase the anti-tumor effect of TMZ in glioma, validated by CD147 shRNA in this study. The gene discussed is NFE2L2; the disease is neoplasm.